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Abstract
Background: There is growing interest in soluble biomarkers that could be used on the group level for screening purposes
in small proof of principle studies during early drug development. We investigated early changes in serum levels of several
candidate biomarkers involved in cartilage and bone metabolism following the initiation of adalimumab as a prototypic
active treatment in psoriatic arthritis (PsA) compared to placebo.
Materials and Methods: Twenty-four PsA patients were randomized to receive either adalimumab 40 mg s.c. every other
week or placebo for 4 weeks, followed by an open label extension phase. Serum samples were obtained at baseline and
after 4 and 12 weeks of treatment and analyzed for levels of CPII and PINP (synthesis of type II and type I procollagen),
melanoma inhibitory activity (MIA) (chondrocyte anabolism), matrix metalloproteinase (MMP)-3, C2C and cartilage
oligomeric matrix protein (COMP) (type II collagen degradation), osteocalcin (OC) (bone formation), NTX-I and ICTP (both
type I collagen degradation).
Results: After 4 weeks, there was a significant decrease in serum MMP-3 levels in adalimumab-treated patients (P,0.005),
while no change was observed in the placebo group. A significant increase in serum MIA was noted after adalimumab
therapy (P,0.005) but not after placebo treatment. After 12 weeks, there was a marked reduction in serum MMP-3 in both
groups (P,0.005), whereas other markers did not show significant changes compared to baseline.
Conclusion: MMP-3 and MIA could serve as soluble biomarkers associated with inflammation as well as joint remodelling
and destruction and may, together with clinical evaluation and in combination with other biomarkers, assist in
distinguishing between effective and ineffective therapy in small, proof-of-principle studies of short duration in PsA.
Trial Registration: Current Controlled Trials ISRCTN23328456
Citation: van Kuijk AWR, DeGroot J, Koeman RC, Sakkee N, Baeten DL, et al. (2010) Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of
Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo. PLoS ONE 5(9): e12556. doi:10.1371/journal.pone.0012556
Editor: Francois Patrick Rannou, Ho ˆpital Cochin, France
Received February 7, 2010; Accepted July 12, 2010; Published September 3, 2010
Copyright:  2010 van Kuijk et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by Abbott (www.abbott.com), after agreement to the protocol. The funder had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: PPT served as a consultant to Abbott. JD and NS are employees of the Netherlands Organization for Applied Scientific Research (TNO),
which is active in 5 core areas of Quality of Life that deal with health-related research. TNO was founded by law in 1932 to enable business and governmentt o
apply knowledge. As a not-for-profit organization regulated by public law, it is an independent research organisation, not part of any government, university or
company. The authors confirm their adherence to all the PLoS ONE policies on sharing data and materials, as outlined in detail in the guide for authors http://
www.plosone.org/static/policies.action#sharing.
* E-mail: P.P.Tak@amc.uva.nl
Introduction
The peripheral arthritis in psoriatic arthritis (PsA) is character-
ized by progressive destruction in the majority of patients [1]. The
articular damage develops over months to years, but can often be
detected within 2 years of the first consultation of a rheumatologist
[2]. The chronic inflammation of the synovial membrane is
thought to be responsible for degradation of cartilage and bone, in
part by locally produced cytokines and proteinases. Treatment
with conventional antirheumatic drugs can improve the clinical
manifestations and inhibit permanent joint damage, but these
drugs are not effective in or tolerated by all patients. New targeted
therapies, such as tumor necrosis factor (TNF) blockade, have
expanded therapeutic possibilities, but not all patients respond well
[3,4]. Therefore, there is still a need for new and better treatment
options, and several new therapeutic strategies are in the pipeline
of pharmaceutical industry. The increase in the development of
numerous new, targeted therapies clearly raises the need for
sensitive biomarkers which could be used on the group level for
early selection of potentially effective treatments.
It has recently been proposed to use small, intensive studies
providing a high density of data to obtain initial proof of principle
in an early stage of drug development before larger, conventional
clinical trials are conducted to determine whether the effects of a
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additional biological data is collected alongside conventional
measures of disease activity to determine if there is a biological
effect related to the mechanism of action of the drug tested. We
have previously shown that synovial biomarkers may be used in
this context in clinical trials in both rheumatoid arthritis (RA) and
PsA [6,7]. The use of soluble biomarkers could increase the
feasibility of this approach, as synovial biopsy is not routinely
available in all centers. Moreover, various biomarkers could be
combined together with clinical evaluation for initial assessment of
efficacy.
The treatment objectives in PsA are not limited to improvement
of clinical signs and symptoms, but include protection against joint
destruction. Since structural damage outcomes require lengthy
clinical trials, the availability of biomarkers associated with these
long-term endpoints would be an attractive therapeutic develop-
ment strategy, especially in early phase trials when decisions are
being made whether and how to proceed with pivotal clinical
trials. For this reason, biologic markers of bone and cartilage
metabolism are of particular interest, because they may reflect
changes related to the integrity of the affected joints [8,9].
Bone matrix is mainly composed of type I collagen, while type II
collagen is the main collagen in articular cartilage. Type I collagen
telopeptide fragments, such as C-terminal cross-linked telopeptide
of type I collagen (CTX-I and ICTP) and N-terminal cross-linked
telopeptide of type I collagen (NTX) in serum are currently
considered to be sensitive markers of bone resorption [10]. ICTP is
released from bone type I collagen by activity of matrix
metalloproteinases (MMPs), while CTX-I is generated by
cathepsin K activity, but not MMPs [11]. Pro-collagen serum
type I N-terminal propeptide (PINP) and osteocalcine (OC) are
markers of bone formation.
Type II collagen synthesis can be detected by measurement of
C-propeptide of type II collagen (CPII), while cartilage degrada-
tion by collagenases can be detected in serum by cleavage products
of type II collagen, such as Col2-3/4C (C2C) and cartilage
oligomeric matrix protein (COMP) [12]. Of importance, several
studies in patients with inflammatory arthritis have shown that
some of these markers of bone and cartilage metabolism are
associated with progression of radiographic joint damage [13–15],
and that their tissue expression and serum levels may change after
initiation of effective (biologic) therapy [13,16–19]. Similarly, it has
been suggested that melanoma inhibitory activity (MIA), also
known as cartilage-derived retinoic acid-sensitive protein (CD-
RAP), a marker for chondrocyte anabolism, could be used as a
biomarker in patients with RA [20]. MIA is suppressed by pro-
inflammatory cytokines in vitro, and serum MIA levels are
increased after one year of infliximab treatment in patients with
inflammatory arthritis [21].
The early effects of active treatment on synovial biomarkers,
following the initiation of adalimumab as a prototypic active
treatment compared to placebo, have recently been reported for
this study cohort of patients with active PsA [6]. As a secondary
endpoint in this study, we investigated early changes in serum
levels of several candidate soluble biomarkers involved in
formation and degradation of cartilage and bone, following the
initiation of adalimumab treatment compared to placebo in the
same cohort of patients. The results on soluble biomarkers
presented in this paper are supplementary to the results previously
published on synovial biomarkers. The ultimate goal of our studies
is to identify biomarkers that could be used in combination as a
screening tool to differentiate on the group level between
potentially effective and ineffective treatments in small proof of
principle studies during an early stage of clinical development.
Materials and Methods
Study protocol
The study protocol was approved by the Medical Ethical
Committee of the Academic Medical Centre/University of
Amsterdam (ref: MEC 05/162, ISRCTN23328456), and all
patients gave their written informed consent. The protocol for
this trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1.
Patients
Twenty-four active PsA patients fulfilling the CASPAR classifica-
tion criteria for PsA [22], were randomized to receive adalimumab
40 mg s.c. every other week (n=12) or matched placebo (n=12) for
4 weeks, followed by an open label extension phase during which all
patients were treated with adalimumab. Most patients (n=16) had
polyarticular involvement according to the Moll and Wright
classification [23], a minority had an oligoarticular phenotype
(n=7) or predominantly distal interphalangeal involvement (n=1).
Two of the patients with polyarticular disease also had axial
involvement. The baseline demographic data are presented in Table
S1. The clinical results of this study have been reported earlier [6].
Serum samples and clinical assessments were obtained at baseline
and after 4 and 12 weeks of treatment. In addition, erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP) were
determined. The disease activity score evaluated in 28 joints
(DAS28), which has been shown to discriminate between active
drug and placebo in clinical trials in PsA, was chosen to monitor
changes in clinical disease activity after therapy [24;25]
Measurement of markers of cartilage and bone
metabolism
N-MID Osteocalcin (ELISA, Nordic Bioscience Diagnostics A/
S, Herlev, Denmark), PINP (UniQ RIA, Orion Diagnostica,
Espoo, Finland), NTX (ELISA, Osteomark, Inverness Medical
Professional Diagnostics, Princeton, New Jersey, USA), ICTP
(UniQ EIA, Orion Diagnostica, Espoo, Finland), CPII (ELISA,
IBEX Pharmaceuticals Inc, Montreal, Canada), C2C (ELISA,
IBEX Pharmaceuticals Inc, Montreal, Canada), COMP (ELISA,
AnaMar Medical, Goteborg, Sweden), and serum MMP-3
(Quantikine ELISA, R&D Systems, Abingdon, UK) levels were
were determined at TNO (Leiden, The Netherlands) according to
the instruction provided by the assay’s manufacturers. Also, serum
MMP-3 was measured. MIA, a marker for cartilage anabolism,
was determined using a commercially available one step ELISA kit
(Roche Diagnostics, Mannheim, Germany) following the manu-
facturer’s instruction.
Statistical analysis Parameters with a normal distribution were
analyzed using a paired samples t-test, while parameters with a
skewed distribution were assessed with the Wilcoxon signed rank
test. In addition, each of the endpoints at week 4 (including ESR
and CRP) was analyzed using a repeated measure analysis of
covariance model (ANCOVA). The model included terms for
treatment as a fixed effect and the baseline measurement as a
covariate with the aim to assess the treatment difference.
Correlations of changes in clinical parameters and serum markers
were analyzed with Spearman’s rank correlation.
Results
Clinical response
We have previously described the primary clinical outcome
after 4 weeks adalimumab versus placebo treatment, as well as the
results of synovial tissue analysis [6]. At week 12, when all 24
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patients decreased from 4.8661.14 at baseline to 2.8461.36 at
week 12 (P,0.001), mean CRP was reduced from 15.0619.5 to
2.864.9 mg/l (P=0.003) and ESR decreased from 23.3619.8 to
7.266.1 mm in 1
st hour (P,0.001).
Markers of type I collagen metabolism (bone) and type II
collagen metabolism (cartilage)
The results of the markers tested are presented in Table S2.
After 4 weeks of adalimumab therapy there was a significant
decrease in median (6 SD) serum MMP-3 levels in adalimumab
treated patients from 41.0635.1 to 14.5612.6 ng/ml (P,0.005),
while no change was observed in the placebo group. After 12
weeks, when all patients were treated with adalimumab, median
serum (6 SD) MMP-3 levels in both groups were reduced
significantly (P,0.005) as shown in Table S2 and Figure S1.
Median (6 SD) serum MIA levels increased significantly after
treatment with adalimumab from 5.7763.3 at baseline to
6.7464.3 ng/ml at week 4 (P,0.005), while serum levels after
placebo treatment were unchanged. After 12 weeks the change in
MIA did not reach statistical significance in either group, as shown
in Table S2 and Figure S2.
Overall, no significant early change in the serum levels of these
bone and cartilage markers was observed. There was a trend
towards a reduction of median (6 SD) serum level NTx in the
adalimumab group from 91.9634.3 at baseline to 75.3623.8 nM
BCE after 4 weeks of treatment (P=0.078), while NTx levels in
the placebo group remained unchanged. There were no significant
changes in NTx at week 12. We also found a trend towards an
increase of median (6 SD) CPII concentrations in the adalimu-
mab treated group from 6686169 at baseline to 7656167 ng/ml
after 4 weeks (P=0.053), while CPII levels in the placebo group
did not change. At week 12 there was a non-significant reduction
of CPII level in both groups. The biological meaning of these
findings is at present uncertain.
When the repeated measure ANCOVA was applied for each of
the endpoints at week 4, the effect of active treatment was
significant for the reduction of ESR (P=0.001), CRP (P=0.01),
and serum MMP-3 (P=0.006), as well as for the increase of serum
MIA level (P=0.013), indicating that these biomarkers could
distinguish between effective and ineffective treatment (Table S3).
Correlation between clinical improvement and changes
in serum biomarkers
Change in DAS28 at week 4 was strongly correlated with change
in CRP (rho 0.755, P,0.001), ESR (Spearman’s rho 0.737,
P,0.001), MMP-3 (rho 0.709, P,0.01) and MIA (rho -0.507,
P,0.01) as shown in Table S3.
Discussion
This placebo-controlled trial with adalimumab in patients with
PsA was conducted to explore if serum biomarkers of cartilage and
bone metabolism could be used to screen for potential efficacy on
the group level in small, early phase trials of short duration. The
recent rise in new drugs discovered may have consequences for the
way these potential novel therapies are tested in patients. This is
usually done in relatively large, placebo-controlled clinical trials. It
has become increasingly difficult to enrol a large number of patients
with active disease in these trials, because of the growing number of
compounds to be tested, and the fact that effective treatment is
available for many patients. Therefore, in an early stage of drug
development it could be favourable to test potential drugs in a short
intensive proof of principle trial for selection purposes, using a small
number of patients in which a large amount of data is collected. If
no clinical or biological effect is found in such a trial, the compound
appears less likely to be effective in a larger clinical trial of longer
duration. If, on the other hand, there is a clear clinical and/or
biological effect, the compound may be effective, and could be
considered for conventional phase 2 clinical trials to determine
whether these effects appear clinically meaningful. Our results
suggest that MMP-3 and perhaps MIA may be instrumental as a
screening method to test new drug candidates for PsA requiring
relatively small numbers of subjects. Obviously, the results
presented here need to be confirmed and validated in a comparable
study design using another effective drug with a different
mechanism of action, for instance ustekinumab [26], for which this
study provides the rationale.
We found a rapid and strong reduction of serum MMP-3, a
matrix metalloproteinase that is involved in inflammation as well
as degradation of cartilage and bone, after initiation of
adalimumab therapy. The effect of treatment on reduction of
MMP-3 in serum was comparable with the reduction of measures
of inflammation (CRP levels and ESR) in the ANCOVA model.
The change in serum MMP-3 levels also strongly correlated with
clinical improvement as measured by DAS28. The observed
changes in MMP-3 concentration are interesting for 2 reasons.
First, this may reflect a change in cartilage degradation in the
affected joints, while the assessment of CRP and ESR merely
represents a change in inflammation. Secondly, it is of particular
interest in patients with PsA, because these patients do not always
have elevated levels of CRP and ESR, even while their disease is
active. The decrease in MMP-3 was sustained up to 12 weeks.
It has been shown that serum MMP-3 levels are elevated in
patients with inflammatory arthritis compared with healthy controls
[27–30].Thereisstillcontroversy,however,whetherbaselineMMP-
3 level or changeinMMP-3 level after treatmentaregood predictors
for future radiographic progression in individual patients. While
some authors find an association between baseline MMP-3 and
subsequent radiographic joint damage [28,31–33], some do not
[34,35]. Evidence for a correlation between radiographic progres-
sion and reduction of MMP-3 level after treatment was reported by
onlyone group[36]. The rapid decreaseofserum MMP-3 level after
TNF blocking therapy is in line with earlier observations in patients
with spondyloarthritis (SpA). In a study with 22 patients with active
SpA who were treated with infliximab (n=12 including 6 PsA
patients) or placebo (n=10) [19], there was a significant reduction of
serum MMP-3 level one week after start of infliximab treatment,
which was sustained up to week 12, while no changes were observed
in the placebo treated patients. Similarly, an open-label study
showed a significant decrease in serum MMP-3 levels 12 weeks after
initiationofetanercepttreatmentin20SpApatients(including6PsA
patients) [37]. In patients with ankylosing spondylitis treated with
adalimumab (n=38), serum MMP-3 concentration significantly
decreased after 12 weeks of treatment, while it was unchanged after
placebo [38].
We also found an increase of serum MIA, a marker for
chondrocyte activity, after 4 weeks of adalimumab treatment. The
change in serum MIA levels correlated with clinical improvement
as measured by DAS28 at week 4 in the adalimumab treated
patients. It has been demonstrated that serum MIA levels are
reduced in patients with active inflammatory arthritis when
compared to healthy controls [20,21]. A 39% increase of serum
MIA concentration was observed in 15 RA patients one year after
start with infliximab, as compared to a 20% increase in 25 SpA
patients [21]. In a subset of 7 RA patients receiving infliximab, it
was demonstrated that this increase in serum MIA level was
detectable from week 30 and beyond. Of interest, we observed a
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adalimumab treatment in PsA patients after 4 weeks, but after 12
weeks no significant effect could be detected. This could indicate
that initiation of adalimumab therapy in PsA patients induces a
short period of enhanced chondrocyte activity in PsA patients after
initiation of adalimumab therapy, which returns to normal after
several weeks. However, the control group did not show an
increase in MIA level after initiation of adalimumab. More data
are obviously needed to understand the underlying mechanism of
MIA regulation and the effect of TNF blockade.
Only small (trends towards) changes were observed in the other
markers tested after initiation of TNF blocking therapy. Although
these trends may reflect an important biological mechanism, these
markers may not be the best candidates to assess effective therapy in
earlyphaseclinicaltrialsofshortduration.MMP-3seemsto be more
responsive to change than the other markers involved in cartilage
breakdown. The lack of change of the other markers might be
explained in part by the relatively short study duration. The goal of
our study was to identify biomarkers that may help to distinguish
between effective and ineffective therapy in proof of principle studies
of short duration. We cannot exclude the possibility that changes
would be seen for CPII and COMP after more prolonged treatment
In conclusion, adalimumab therapy in PsA is associated with a
specific and highly significant decrease in serum MMP-3 and an
increase in serum MIA levels, suggesting that the measurement of
these soluble biomarkers, known to be associated with the effects
on the structural integrity of the joints, could be useful for
screening purposes on the group level in proof of principle trials
during early drug development.
Supporting Information
Checklist S1 Consort checklist.
Found at: doi:10.1371/journal.pone.0012556.s001 (0.19 MB
DOC)
Figure S1 Changes in serum levels of MMP-3 in relationship to
treatment. Median and interquartile ranges are shown for serum
MMP-3 concentrations in ng/ml at baseline and weeks 4 and 12 for
the patients originally randomized to receive adalimumab (panel A),
or placebo (panel B). After 4 weeks of adalimumab therapy, there was
asignificantdecreaseinmedian(6SD) serum MMP-3 concentration
in adalimumab-treated patients from 41.0635.1 to 14.5612.6 ng/
ml (* P,0.005), and this reduction was sustained at week 12 (panel
A). No change in median serum MMP-3 concentration was observed
in the placebo group at week 4, but after open label adalimumab
treatment from week 4 to week 12, there was a decrease in MMP-3
levels in this group as well (* P,0.005, panel B).
Found at: doi:10.1371/journal.pone.0012556.s002 (0.07 MB TIF)
Figure S2 Changes in serum levels of MIA in relationship to
treatment. Median and interquartile ranges are shown for serum
MIA concentrations in ng/ml at baseline and weeks 4 and 12 for
the patients originally randomized to receive adalimumab (panel
A), or placebo (panel B). After 4 weeks, median(6 SD) serum MIA
concentration in adalimumab-treated patients increased signifi-
cantly from 5.7763.3 at baseline to 6.7464.3 at week 4 (*
P,0.005), but this was not significant at week 12 (panel A). No
significant changes were noted in serum MIA concentration in the
placebo-treated patients at week 4, or at week 12 after receiving
open label adalimumab from week 4 to 12 (panel B).
Found at: doi:10.1371/journal.pone.0012556.s003 (0.06 MB TIF)
Protocol S1 Trial protocol.
Found at: doi:10.1371/journal.pone.0012556.s004 (0.50 MB
DOC)
Table S1 Demographic and clinical features of the 24 patients with
psoriatic arthritis (PsA) enrolled in the study. All values are presented
as mean (range) except where indicated otherwise. PA, polyarticular;
OA, oligoarticular; DIP, predominant distal interphalangeal; RF,
rheumatoid factor; ACPA, anti-citrillunated protein antibody; MTX,
methotrexate; ESR, erythrocyte sedimentation rate; CRP,C-reactive
protein; DAS28, disease activity score in 28 joints; VAS, visual
analogue scale; PASI, psoriasis area end severity index.
Found at: doi:10.1371/journal.pone.0012556.s005 (0.04 MB
RTF)
Table S2 Results of markers of collagen type I and collagen type
II in placebo and adalimumab treated groups. All values are
presented as median (standard deviation, SD). ** P,0.005. NTx,
N-terminal telopeptide of type I collagen; PINP, pro-collagen type
I N-terminal propeptide; ICTP, C-terminal telopeptide of type I
collagen; OC, osteocalcine; MMP-3, matrix metalloproteinase-3;
MIA, melanoma inhibitory activity; CPII, C-propeptide of type II
collagen; COMP, cartilage oligomeric matrix protein; C2C, Col2-
3/4C.
Found at: doi:10.1371/journal.pone.0012556.s006 (0.04 MB
DOC)
Table S3 P-values of the repeated measure ANCOVA for each
marker, including ESR and CRP. The correlation between each
marker, including ESR and CRP, and change in the disease
activity evaluated in 28 joints (DAS28) are presented as Spearman
rho (P-value).
Found at: doi:10.1371/journal.pone.0012556.s007 (0.03 MB
DOC)
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